BWAY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

25.000

Open

24.000

VWAP

24.00

Vol

96.00K

Mkt Cap

481.00M

Low

22.972

Amount

2.00M

EV/EBITDA(TTM)

86.00

Total Shares

20.00M

EV

407.00M

EV/OCF(TTM)

18.00

P/S(TTM)

11.00

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Show More

Events Timeline

(ET)

2026-01-21

07:40:00

BrainsWay Announces Highmark Expands Depression Treatment Coverage

2026-01-12 (ET)

2026-01-12

07:50:00

BrainsWay Receives FDA Approval for ProlivRx to Treat Major Depressive Disorder

2026-01-07 (ET)

2026-01-07

07:40:00

BrainsWay Expands Coverage for Patients 15 and Older with MDD

2025-12-22 (ET)

2025-12-22

07:40:00

BrainsWay Expands Deep TMS Coverage to Adolescents 15 and Older via Optum

2025-11-17 (ET)

2025-11-17

07:40:41

Brainsway Initiates First Trial of Deep TMS 360 System for Alcohol Use Disorder

2025-11-13 (ET)

2025-11-13

06:06:18

FDA Approves Brainsway's Deep TMS Device for Major Depressive Disorder

News

an image of Benzinga

Wall Street Analysts Adjust Ratings on Key Stocks

an image of Globenewswire

01-21Globenewswire

BrainsWay Secures Expanded Coverage for Depression Treatment from Highmark

an image of Globenewswire

01-12Globenewswire

BrainsWay (BWAY) Receives FDA Approval for Proliv™Rx System for Depression Treatment

an image of Newsfilter

2025-11-25Newsfilter

BrainsWay to Host Virtual Analyst & Investor Day on December 1, 2025

an image of Newsfilter

2025-11-13Newsfilter

BrainsWay Obtains FDA Approval for Deep TMS™ as Additional Treatment for Major Depressive Disorder in Teens Aged 15 to 21

an image of Benzinga

2025-11-12Benzinga

Northland Capital Markets Reaffirms Outperform Rating for BrainsWay, Increases Price Target to $23

3 Analyst Rating

Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is 22.00 USD with a low forecast of 19.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

22.00

High

24.00

Current: 0.000

Low

19.00

Averages

22.00

High

24.00

H.C. Wainwright

H.C. Wainwright

maintain

$24 -> $30

AI Analysis

2026-01-26

New

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$24 -> $30

AI Analysis

2026-01-26

New

maintain

Reason

H.C. Wainwright raised the firm's price target on Brainsway to $30 from $24 and keeps a Buy rating on the shares. The company recently announced premarket approval receipt for Neurolief's Proliv RX system, a class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic, the analyst tells investors in a research note.

Northland

Outperform

maintain

$23 -> $30

2026-01-22

Reason

Northland

Price Target

$23 -> $30

2026-01-22

maintain

Outperform

Reason

Northland raised the firm's price target on Brainsway to $30 from $23 and keeps an Outperform rating on the shares. The firm believes that its FDA-approved SWIFT accelerated protocol and its strategic partnerships will boost both near and long-term prospects, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BWAY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Brainsway Ltd (BWAY.O) is 83.87, compared to its 5-year average forward P/E of 36.37. For a more detailed relative valuation and DCF analysis to assess Brainsway Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

36.37

Current PE

83.87

Overvalued PE

124.31

Undervalued PE

-51.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-1.40

Current EV/EBITDA

28.62

Overvalued EV/EBITDA

12.21

Undervalued EV/EBITDA

-15.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

3.31

Current PS

6.24

Overvalued PS

4.76

Undervalued PS

1.86

Financials

AI Analysis

Annual

Quarterly

Whales Holding BWAY

Trading Trends

People Also Watch

Frequently Asked Questions

What is Brainsway Ltd (BWAY) stock price today?

The current price of BWAY is 24.05 USD — it has decreased -2.67 % in the last trading day.

What is Brainsway Ltd (BWAY)'s business?

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

What is the price predicton of BWAY Stock?

Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is22.00 USD with a low forecast of 19.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Brainsway Ltd (BWAY)'s revenue for the last quarter?

Brainsway Ltd revenue for the last quarter amounts to 14.00M USD, increased 28.66 % YoY.

What is Brainsway Ltd (BWAY)'s earnings per share (EPS) for the last quarter?

Brainsway Ltd. EPS for the last quarter amounts to 0.04 USD, increased 100.00 % YoY.

How many employees does Brainsway Ltd (BWAY). have?

Brainsway Ltd (BWAY) has 120 emplpoyees as of January 30 2026.

What is Brainsway Ltd (BWAY) market cap?

Today BWAY has the market capitalization of 481.00M USD.